NEW YORK – Caris Life Sciences said on Tuesday that it has inked an agreement with Moderna to support the development of mRNA-based cancer therapeutics.
Financial terms of the deal were not disclosed.
Through the multiyear partnership agreement, Moderna will get access to Caris' library of de-identified, multimodal data derived from whole-exome sequencing, whole-transcriptome sequencing, protein analyses, and claims data. This will help Moderna design clinical trials, discover novel biomarkers, and characterize resistance mechanisms.
Based in Irving, Texas, Caris claims it has created "the largest clinico-genomic database coupled with cognitive computing to unravel the molecular complexity of disease." The company has formed similar partnerships for cancer research and development with ConcertAI and Flare Therapeutics.